营养食品代工

Search documents
衡美健康北交所IPO前夜:自身产能闲置、核心客户流失 估值超20亿留不住创始成员高管?
Xin Lang Zheng Quan· 2025-08-22 06:28
Core Viewpoint - The nutritional supplement companies, including汤臣倍健 and 巨星传奇, are facing significant declines in revenue and profit, while the contract manufacturer 衡美健康 is preparing for an IPO despite recent operational challenges [1][2]. Group 1: Company Performance -汤臣倍健's revenue and net profit both decreased in the first half of 2025, with its stock price dropping from a peak of 33.28 yuan to below 10 yuan, resulting in a market value loss of 42 billion yuan [1]. -巨星传奇 expects a comprehensive profit of no more than 8.5 million yuan for the first half of 2025, a 67% drop compared to 25.5 million yuan in the same period of 2024 [1]. -衡美健康's revenue grew from 587 million yuan in 2022 to 1.072 billion yuan in 2024, with a net profit increase from 39.84 million yuan to 103 million yuan, reflecting compound annual growth rates of 22.2% and 37.3% respectively [1]. Group 2: Sales and Production Challenges - In Q1 2025,衡美健康's total revenue was 217 million yuan, a 10.1% year-on-year decline, and net profit fell by 23.1% to 20.06 million yuan [1]. - The company experienced a significant drop in sales across various product categories, with烘焙类, 糖果类, and 棒类 products seeing year-on-year decreases of 8.6%, 17.4%, and 22.7% respectively [5]. - Despite the decline in sales,衡美健康 plans to invest 249 million yuan in expanding its production capacity, which raises questions about the necessity and urgency of such expansion given the current underutilization of capacity [7]. Group 3: Client Dependency and Risks -衡美健康's top five clients accounted for 55.3%, 45.6%, and 49.7% of total revenue from 2022 to 2024, indicating a high concentration of revenue sources [7]. - The loss of key clients, such as Wonderlab, which has shifted to self-manufacturing, poses a risk to衡美健康's revenue stability [8]. - The company may face increased competition and potential price wars as it attempts to retain existing clients and attract new ones amid declining sales [9]. Group 4: IPO and Valuation -衡美健康 plans to issue up to 16.67 million shares to raise 501 million yuan, which would value the company at approximately 2 billion yuan, a 55-fold increase from its valuation in 2021 [10]. - Concerns have been raised regarding the company's governance, as several key executives, including the founder, have resigned prior to the IPO, leading to scrutiny from the 北交所 [11][12].